Do phenothiazines contribute to tumour regressions in lymphokine-activated killer cell/interleukin-2 treatments of renal cell cancer?
D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D007694:Killer Cells, Natural / Q000276:immunology; D008222:Lymphokines / Q000276:immunology; D010640:Phenothiazines / Q000627:therapeutic use*
D007376:Interleukin-2; D008222:Lymphokines; D010640:Phenothiazines